186 related articles for article (PubMed ID: 21196211)
1. Investigations of survivin: the past, present and future.
Cheung CH; Cheng L; Chang KY; Chen HH; Chang JY
Front Biosci (Landmark Ed); 2011 Jan; 16(3):952-61. PubMed ID: 21196211
[TBL] [Abstract][Full Text] [Related]
2. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells.
Cheng SM; Chang YC; Liu CY; Lee JY; Chan HH; Kuo CW; Lin KY; Tsai SL; Chen SH; Li CF; Leung E; Kanwar JR; Huang CC; Chang JY; Cheung CH
Br J Pharmacol; 2015 Jan; 172(1):214-34. PubMed ID: 25220225
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
[TBL] [Abstract][Full Text] [Related]
4. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.
Ghadimi MP; Young ED; Belousov R; Zhang Y; Lopez G; Lusby K; Kivlin C; Demicco EG; Creighton CJ; Lazar AJ; Pollock RE; Lev D
Clin Cancer Res; 2012 May; 18(9):2545-57. PubMed ID: 22407831
[TBL] [Abstract][Full Text] [Related]
5. The role of survivin in the diagnosis and therapy of gynaecological cancers.
Denel-Bobrowska M; Marczak A
Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1182-1189. PubMed ID: 28026821
[TBL] [Abstract][Full Text] [Related]
6. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.
Jane EP; Premkumar DR; DiDomenico JD; Hu B; Cheng SY; Pollack IF
Mol Cancer Ther; 2013 Mar; 12(3):326-38. PubMed ID: 23325792
[TBL] [Abstract][Full Text] [Related]
7. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers.
Cheung CH; Chen HH; Kuo CC; Chang CY; Coumar MS; Hsieh HP; Chang JY
Mol Cancer; 2009 Jul; 8():43. PubMed ID: 19575780
[TBL] [Abstract][Full Text] [Related]
8. Cellular inhibitor of apoptosis protein 1 (cIAP1) stability contributes to YM155 resistance in human gastric cancer cells.
Jung SA; Park YM; Hong SW; Moon JH; Shin JS; Lee HR; Ha SH; Lee DH; Kim JH; Kim SM; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Jin DH; Kim T
J Biol Chem; 2015 Apr; 290(16):9974-85. PubMed ID: 25635055
[TBL] [Abstract][Full Text] [Related]
9. Survivin and YM155: how faithful is the liaison?
Rauch A; Hennig D; Schäfer C; Wirth M; Marx C; Heinzel T; Schneider G; Krämer OH
Biochim Biophys Acta; 2014 Apr; 1845(2):202-20. PubMed ID: 24440709
[TBL] [Abstract][Full Text] [Related]
10. Examination of survivin expression in 50 chordoma specimens--A histological and in vitro study.
Froehlich EV; Rinner B; Deutsch AJ; Meditz K; Knausz H; Troppan K; Scheipl S; Wibmer C; Leithner A; Liegl B; Lohberger B
J Orthop Res; 2015 May; 33(5):771-8. PubMed ID: 25640185
[TBL] [Abstract][Full Text] [Related]
11. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
[TBL] [Abstract][Full Text] [Related]
12. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
Premkumar DR; Jane EP; Foster KA; Pollack IF
J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
[TBL] [Abstract][Full Text] [Related]
13. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions.
Zaffaroni N; Daidone MG
Drug Resist Updat; 2002 Apr; 5(2):65-72. PubMed ID: 12135582
[TBL] [Abstract][Full Text] [Related]
14. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
[TBL] [Abstract][Full Text] [Related]
15. [Study on apoptosis of oral squamous carcinoma cell line KB and KBv200 induced by survivin RNAi].
Yan L; Chen WQ; Liang YJ; Dai CL; Wang XH; Shi Z; Chen LM; Fu LW
Ai Zheng; 2006 Aug; 25(8):933-40. PubMed ID: 16965671
[TBL] [Abstract][Full Text] [Related]
16. Survivin as a target for new anticancer interventions.
Zaffaroni N; Pennati M; Daidone MG
J Cell Mol Med; 2005; 9(2):360-72. PubMed ID: 15963255
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in anti-survivin treatments for cancer.
Kanwar RK; Cheung CH; Chang JY; Kanwar JR
Curr Med Chem; 2010; 17(15):1509-15. PubMed ID: 20166933
[TBL] [Abstract][Full Text] [Related]
18. Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development.
Kondapuram SK; Ramachandran HK; Arya H; Coumar MS
Life Sci; 2023 Dec; 335():122260. PubMed ID: 37963509
[TBL] [Abstract][Full Text] [Related]
19. The inhibitors of apoptosis (IAPs) and their emerging role in cancer.
LaCasse EC; Baird S; Korneluk RG; MacKenzie AE
Oncogene; 1998 Dec; 17(25):3247-59. PubMed ID: 9916987
[TBL] [Abstract][Full Text] [Related]
20. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
Okamoto K; Okamoto I; Hatashita E; Kuwata K; Yamaguchi H; Kita A; Yamanaka K; Ono M; Nakagawa K
Mol Cancer Ther; 2012 Jan; 11(1):204-13. PubMed ID: 22075159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
